Wimmer Associates 1 LLC increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 100.0% during the third quarter, according to its most recent filing with the SEC. The fund owned 6,490 shares of the company’s stock after buying an additional 3,245 shares during the quarter. Wimmer Associates 1 LLC’s holdings in Henry Schein were worth $532,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Intrust Bank NA boosted its holdings in shares of Henry Schein by 1.1% in the 2nd quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock worth $223,000 after buying an additional 13 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Henry Schein by 4.0% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock valued at $2,719,000 after acquiring an additional 566 shares during the period. Bradley Foster & Sargent Inc. CT raised its stake in Henry Schein by 2.1% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 33,106 shares of the company’s stock valued at $6,059,000 after acquiring an additional 690 shares during the period. Steinberg Global Asset Management raised its stake in Henry Schein by 100.0% in the 3rd quarter. Steinberg Global Asset Management now owns 19,412 shares of the company’s stock valued at $1,592,000 after acquiring an additional 9,706 shares during the period. Finally, Comerica Bank raised its stake in Henry Schein by 10.6% in the 2nd quarter. Comerica Bank now owns 21,833 shares of the company’s stock valued at $4,054,000 after acquiring an additional 2,101 shares during the period. 91.69% of the stock is currently owned by institutional investors.
Shares of Henry Schein, Inc. (HSIC) traded down $0.68 on Friday, hitting $69.88. The stock had a trading volume of 972,702 shares, compared to its average volume of 1,665,463. Henry Schein, Inc. has a 12-month low of $65.28 and a 12-month high of $93.50. The company has a market capitalization of $11,074.70, a PE ratio of 20.14, a PEG ratio of 1.99 and a beta of 0.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55.
Henry Schein declared that its board has authorized a stock buyback program on Monday, September 18th that authorizes the company to repurchase $400.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 6.3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
A number of equities research analysts recently issued reports on HSIC shares. Jefferies Group restated a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a research note on Thursday, September 28th. Morgan Stanley cut Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price objective on the stock. in a research note on Wednesday, December 6th. Zacks Investment Research cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Robert W. Baird set a $95.00 price objective on Henry Schein and gave the company a “buy” rating in a research note on Thursday, October 19th. Finally, UBS Group restated a “buy” rating on shares of Henry Schein in a research note on Friday, September 15th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $86.21.
In other news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares in the company, valued at $3,408,650.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.19% of the company’s stock.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.